GSK RSV Vaccine Achieves 75.6% Hospitalization Protection, Analysts Raise Targets
GSK's RSV vaccine AREXVY demonstrated 75.6% effectiveness against hospitalization and 63.1% effectiveness against major adverse cardiovascular events over a median 5.6-month follow-up. GSK shares trade 5.9% above their 20-day SMA and 11.5% above their 100-day SMA after a 42.1% annual gain and several raised price targets.
1. Vaccine Effectiveness Data
GSK reported that AREXVY achieved 75.6% vaccine effectiveness against RSV-related hospitalization at a median 5.6-month follow-up (maximum 9.7 months). Exploratory results also showed 63.1% effectiveness against major adverse cardiovascular events, underscoring potential broader protective benefits.
2. Stock Technicals and Analyst Actions
Shares trade 5.9% above the 20-day SMA and 11.5% above the 100-day SMA, reflecting a 42.13% gain over the past 12 months. The RSI sits at 69.29 (neutral) and MACD at 3.7853 (bullish), with key resistance at $123.50 and support at $120.00. Analyst consensus carries a Buy rating with an average target of $119.95; Guggenheim raised its target to $140, while Citigroup and Cantor Fitzgerald set neutral targets at $120.